Drugs / RN6G
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01003691 | Aug 2010 → Mar 2013 | age-related macular degeneration | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00877032 | Apr 2009 → Jul 2011 | age-related macular degeneration | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01577381 | Aug 2012 → Sep 2013 | age-related macular degeneration | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RN6G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01003691 ↗ |
| Known as | PF-04382923 | “A PHASE 1, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING DOSAGES OF...” NCT01003691 ↗1“A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g...” NCT01577381 ↗ |
| Route | Intravenous | “intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.” NCT00877032 ↗ |